Similar articles for PMID: 26693800

Year	Number of Results
1991	1
1993	1
1995	1
1997	1
1998	1
1999	2
2000	3
2002	7
2003	1
2004	1
2005	3
2006	1
2007	5
2008	2
2009	2
2010	9
2011	5
2012	3
2013	7
2014	5
2015	6
2016	16
2017	11
2018	8
2019	9
2020	4
2021	5
2022	9
2023	1
2024	0

1

Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.

Sasse S, Alram M, Müller H, Smardová L, Metzner B, Doehner H, Fischer T, Niederwieser DW, Schmitz N, Schäfer-Eckart K, Raemaekers JM, Schmalz O, Tresckow BV, Engert A, Borchmann P. Sasse S, et al. Leuk Lymphoma. 2016 May;57(5):1067-73. doi: 10.3109/10428194.2015.1083561. Epub 2015 Dec 23. Leuk Lymphoma. 2016. PMID: 26693800 Clinical Trial.

2

Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.

Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N. Abali H, et al. Cancer Invest. 2008 May;26(4):401-6. doi: 10.1080/07357900701788098. Cancer Invest. 2008. PMID: 18443961

3

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A; Participating Centers. Josting A, et al. Ann Oncol. 2002 Oct;13(10):1628-35. doi: 10.1093/annonc/mdf221. Ann Oncol. 2002. PMID: 12377653 Free article. Clinical Trial.

4

Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).

Gillessen S, Hüttmann A, Vucinic V, Müller H, Plütschow A, Viardot A, Topp MS, Kobe C, Böll B, Eichenauer DA, Sasse S, Haverkamp H, Schmitz C, Borchmann S, Bröckelmann PJ, Heger JM, Fuchs M, Engert A, Borchmann P, von Tresckow B. Gillessen S, et al. Br J Haematol. 2022 Feb;196(3):606-616. doi: 10.1111/bjh.17878. Epub 2021 Nov 14. Br J Haematol. 2022. PMID: 34775591 Clinical Trial.

5

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.

Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. Rancea M, et al. Cochrane Database Syst Rev. 2013 Jun 20;(6):CD009411. doi: 10.1002/14651858.CD009411.pub2. Cochrane Database Syst Rev. 2013. PMID: 23784872 Review.

6

Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.

Haq R, Sawka CA, Franssen E, Berinstein NL. Haq R, et al. Leuk Lymphoma. 1999 Nov;35(5-6):527-36. doi: 10.1080/10428199909169617. Leuk Lymphoma. 1999. PMID: 10609790 Clinical Trial.

7

Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.

Schirmbeck NG, Mey UJ, Olivieri A, Ko YD, Kaiser U, Flieger D, Witzens-Harig M, Schmidt-Wolf IG. Schirmbeck NG, et al. Cancer Invest. 2016 Sep 13;34(8):361-72. doi: 10.1080/07357907.2016.1212062. Epub 2016 Sep 16. Cancer Invest. 2016. PMID: 27635469

8

Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.

Sinha R, Shenoy PJ, King N, Lechowicz MJ, Bumpers K, Hutcherson D, Arellano M, Langston A, Kaufman J, Heffner LT Jr, Waller EK, Nooka A, Flowers CR, Lonial S. Sinha R, et al. Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):657-63. doi: 10.1016/j.clml.2013.05.007. Epub 2013 Oct 2. Clin Lymphoma Myeloma Leuk. 2013. PMID: 24094894

9

Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.

Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, Daw S. Shankar A, et al. Br J Haematol. 2014 May;165(4):534-44. doi: 10.1111/bjh.12768. Epub 2014 Feb 7. Br J Haematol. 2014. PMID: 24754633 Free article.

10

Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.

Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO). Martínez C, et al. Br J Haematol. 2016 Sep;174(6):859-67. doi: 10.1111/bjh.14133. Epub 2016 May 17. Br J Haematol. 2016. PMID: 27185197 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

111 results

Results by year